Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 333

The DOI matches its Crossref record.

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

Open access
Eagling, V. A., Back, D. J., Barry, M. G. · 1997 · British Journal of Clinical Pharmacology

Abstract

Aims To compare the inhibitory potential of the HIV protease inhibitors saquinavir, ritonavir and indinavir against CYP1A2, CYP2C9, CYP2E1 and CYP3A4 catalysed metabolic reactions in human liver microsomes in vitro. Methods Microsomes from six human livers were utilized in this study. The probe substrates were phenacetin (CYP1A2), tolbutamide (CYP2C9), chlorzoxazone (CYP2E1) and testosterone (CYP3A4). Metabolites were analysed by high performance liquid chromatography. IC 50 (concentration of inhibitor giving 50% decrease in enzyme activity) and, where appropriate, K i values were calculated. Results Ritonavir was a very potent inhibitor of CYP3A4 mediated testosterone 6β‐hydroxylation (mean K i=0.019±0.004 μm, mean±s.d.; n=6) and also inhibited tolbutamide hydroxylation (IC 50=4.2±1.3 μm, mean±s.d.; n=6). Inhibition of phenacetin O‐deethylation and chlorzoxazone 6‐hydroxylation was negligible. Indinavir was an order‐of‐magnitude less potent in inhibiting CYP3A4 (K i=0.17±0.01 μm ) and did not produce appreciable inhibition of the CYP1A2, CYP2C9 or CYP2E1 catalysed reactions. Saquinavir was the least potent CYP3A4 inhibitor (K i=2.99±0.87 μm ) and produced some inhibition of CYP2C9 (approximately 50% at 50 μm ). Conclusions The HIV protease inhibitors have differential effects on CYP isozymes. There is obvious potential for clinically significant drug interactions particularly with ritonavir. Pharmacokinetic drug interaction studies are crucial to gain an overall understanding of the beneficial and potentially harmful effects of this important group of drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.1997.00644.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 333

Metadata

Authors
Eagling, V. A., Back, D. J., & Barry, M. G.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
1997-08
Volume
44
Issue
2
Pages
190-194
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2078387155
Cited by
333
References
0
FWCI
18.39
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. https://app.cochat.ai/papers/10.1046/j.1365-2125.1997.00644.x
The paper
Eagling, V. A., Back, D. J., & Barry, M. G. (1997). Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.1997.00644.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.